Abattis Bioceuticals Buy Hold or Sell Recommendation

ATTBF -- USA Stock  

USD 0.0293  0.0013  4.64%

Assuming 30 trading days horizon, and your above average risk tolerance our recommendation regarding Abattis Bioceuticals Corp is 'Strong Sell'. Macroaxis provides Abattis Bioceuticals buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding ATTBF positions. The advice algorithm takes into account all of Abattis Bioceuticals Corp available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from ATTBF buy-and-hold prospective. Check also Abattis Bioceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for muliple equity instruments please use Instant Ratings tool.

Time Horizon

Risk Tolerance

Symbol
Execute Advice
Sell Abattis BioceuticalsBuy Abattis Bioceuticals
Strong Sell

Volatility

Hype Condition

Current Valuation

Odds of Distress

Economic Sensitivity

Analyst Consensus

Not Available
For the selected time horizon Abattis Bioceuticals Corp has a mean deviation of 4.23, semi deviation of 0.0, standard deviation of 5.31, variance of 28.25, downside variance of 0.0 and semi variance of 0.0
We provide buy or sell advice to complement the prevailing expert consensus on Abattis Bioceuticals Corp. Our dynamic recommendation engine makes use of multi - dimensional algorithm to analyze the company potential to grow using all technical and fundamental data available at the time. To make sure Abattis Bioceuticals is not overpriced, please confirm all Abattis Bioceuticals Corp fundamentals including its Net Income, Book Value Per Share and the relationship between Revenue and Total Debt . As Abattis Bioceuticals Corp appears to be a penny stock we also recommend to validate its Revenue numbers.

Abattis Bioceuticals Trading Alerts and Improvement Suggestions

Abattis Bioceuticals generates negative expected return over the last 30 days
Abattis Bioceuticals has high historical volatility and very poor performance
Abattis Bioceuticals has some characteristics of a very speculative penny stock
Abattis Bioceuticals has high likelihood to experience some financial distress in the next 2 years
The company reported revenue of 4.44K. Net Loss for the year was (20.73M) with profit before overhead, payroll, taxes, and interest of 46.71K.
ABATTIS BIOCEUTIC has accumulated about 4.78M in cash with (5.47M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01.

Abattis Bioceuticals Returns Distribution Density

Mean Return0.39Value At Risk9.62
Potential Upside9.63Standard Deviation5.31
 Return Density 
      Distribution 

Institutional Investors

Security TypeSharesValue
Winch Advisory Services LlcCommon Shares3 K0.0

Abattis Bioceuticals Greeks

α
Alpha over DOW
=0.5
β
Beta against DOW=0.66
σ
Overall volatility
=5.28
Ir
Information ratio =0.1

Abattis Bioceuticals Volatility Alert

Abattis Bioceuticals Corp exhibits very low volatility with skewness of 0.25 and kurtosis of -0.33. However, we advise investors to further study Abattis Bioceuticals Corp technical indicators to make sure all market info is available and is reliable. Abattis Bioceuticals Corp is a penny stock. Although Abattis Bioceuticals may be in fact a good investment, many penny stocks are subject to artificial stock hype. Make sure you completely understand upside potential and downside risk of investing in Abattis Bioceuticals Corp. We encourage investors to look for the signals such us message board hypes, claims of breakthroughs, email spams, sudden volume upswings, and other similar hype indicators. We also encourage traders to check biographies and work history of company officers before investing in instruments with high volatility. You can indeed make money on this equity instrument if you perfectly time your entry and exit. However, remember that penny stocks that has been the subject of an artificial hype usually unable to maintain its increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The one and only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.
    
 Better Than Average     
    
 Worse Than Average Compare Abattis Bioceuticals to competition

Abattis Bioceuticals Fundamental Vs Peers

FundamentalsAbattis BioceuticalsPeer Average
Return On Equity(78.70)% (0.31)%
Return On Asset(45.23)% (0.14)%
Current Valuation12.55M16.62B
Shares Outstanding406.45M571.82M
Price to Earning(5.83)X28.72X
Price to Book0.23X9.51X
Revenue4.44K9.43B
Gross Profit46.71K27.38B
EBITDA(18.29M)3.9B
Net Income(20.73M)570.98M
Cash and Equivalents4.78M2.7B
Cash per Share0.01X5.01X
Total Debt630.3K5.32B
Debt to Equity1.20% 48.70%
Current Ratio5.71X2.16X
Book Value Per Share0.13X1.93K
Cash Flow from Operations(5.47M)971.22M
Earnings Per Share(0.08)X3.12X
Number of Employees718.84K
Beta1.22-0.15
Market Capitalization12.19M19.03B
Total Asset1.2M29.47B
Retained Earnings(10.13M)9.33B
Working Capital(588K)1.48B
Current Asset260K9.34B
Current Liabilities848K7.9B
Z Score-49.38.72
Search macroaxis.com